Palopegteriparatide
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
The impact of parathyroid hormone replacement with palopegteriparatide on synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism.
Journal: Expert review of clinical pharmacology
Published: August 17, 2026
Erratum: Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug: Erratum.
Journal: Annals of medicine and surgery (2012)
Published: July 11, 2026
Hypoparathyroidism Post Thyroidectomy: Prevention, Evaluation, Management, and Application of Recent Guidelines.
Journal: Thyroid : official journal of the American Thyroid Association
Published: May 22, 2026
Clinical Characteristics, Treatment Patterns, and Complications in Permanent Hypoparathyroidism: A Large Retrospective Cross-Sectional Study.
Journal: Calcified tissue international
Published: April 09, 2026
Palopegteriparatide Therapy for Hypoparathyroidism: Targeting the PTH Receptor Rouses the Sleeping Skeleton.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: March 30, 2026
Hypoparathyroidism: translating science from the laboratory to the clinic.
Journal: The lancet. Diabetes & endocrinology
Published: March 25, 2026
Case Report: Palopegteriparatide as a novel therapeutic option in pediatric autosomal dominant hypocalcemia type 1.
Journal: Frontiers in endocrinology
Published: March 24, 2026
Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study.
Journal: European journal of endocrinology
Published: February 08, 2026
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: January 30, 2026
The key data from the 2025 ESE/ESPE Congress: Chronic hypoparathyroidism in adults.
Journal: Annales d'endocrinologie
Published: January 28, 2026
Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.
Journal: JBMR plus
Published: January 20, 2026
A Novel Method for the Evaluation of Hypercalciuria in Individuals With Chronic Hypoparathyroidism.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: January 20, 2026
Last Updated: 09/26/2026